Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
AstraZeneca
McKesson
Queensland Health
UBS
Chinese Patent Office
Harvard Business School
Deloitte
Moodys

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204031

« Back to Dashboard

NDA 204031 describes XARTEMIS XR, which is a drug marketed by Mallinckrodt Inc and is included in one NDA. It is available from two suppliers. There are thirteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the XARTEMIS XR profile page.

The generic ingredient in XARTEMIS XR is acetaminophen; oxycodone hydrochloride. There are sixty-six drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the acetaminophen; oxycodone hydrochloride profile page.
Summary for 204031
Tradename:XARTEMIS XR
Applicant:Mallinckrodt Inc
Ingredient:acetaminophen; oxycodone hydrochloride
Patents:13
Formulation / Manufacturing:see details
Pharmacology for NDA: 204031
Mechanism of ActionFull Opioid Agonists
Suppliers and Packaging for NDA: 204031
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031 NDA Mallinckrodt, Inc 23635-115 N 23635-115-01
XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031 NDA Mallinckrodt, Inc 23635-115 N 23635-115-62

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength325MG;7.5MG
Approval Date:Mar 11, 2014TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 20, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jun 1, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
Patent:➤ Try a Free TrialPatent Expiration:Mar 11, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Colorcon
Argus Health
Healthtrust
Covington
Dow
Moodys
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot